Funder: American Cancer Society
Due Dates: December 1, 2025 (Application) | June 2025 (Award Notification) | September 2025 (Anticipated Start)
Funding Amounts: Up to $946,000 total (RSG: $215,000/year direct + 10% IDC, 4 years) | Up to $1,892,000 total (Team: $430,000/year direct + 10% IDC, 4 years)
Summary: Supports research into cancer interception and prevention therapies for RUNX1-FPD hematologic malignancies, with a focus on mechanistic understanding and innovative treatment strategies.
Key Information: Applicants may only apply for one mechanism (RSG or Team); eligibility limited to independent investigators at US academic/nonprofit institutions.